Synendos Therapeutics takes in Series A

Synendos Therapeutics, a Swiss biopharmaceutical company focused on treating central nervous system disorders, has raised CHF 20 million (almost $22 million) in Series A financing.

Synendos Therapeutics, a Swiss biopharmaceutical company focused on treating central nervous system disorders, has raised CHF 20 million (almost $22 million) in Series A financing. Kurma Partners and Sunstone Life Science Ventures led the round.

Source: Press Release